{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:09:48Z","timestamp":1771420188574,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Beijing Municipal Administration of Hospitals\u2019 Ascent Plan","award":["(DFL20221402)"],"award-info":[{"award-number":["(DFL20221402)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04696-9","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:15:18Z","timestamp":1768032918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo"],"prefix":"10.1186","volume":"26","author":[{"given":"Zimo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangxue","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"3","key":"4696_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.chest.2021.10.003","volume":"161","author":"K Kumar","year":"2022","unstructured":"Kumar K, Loebinger MR. Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic Features, risk Factors, and diagnosis: the nontuberculous mycobacterial series. Chest. 2022;161(3):637\u201346.","journal-title":"Chest"},{"issue":"12","key":"4696_CR2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/14787210.2016.1238304","volume":"14","author":"F Mougari","year":"2016","unstructured":"Mougari F, et al. Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Rev Anti Infect Ther. 2016;14(12):1139\u201354.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"4696_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-020-00667-6","volume":"27","author":"R Gopalaswamy","year":"2020","unstructured":"Gopalaswamy R, et al. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci. 2020;27(1):74.","journal-title":"J Biomed Sci"},{"key":"4696_CR4","doi-asserted-by":"publisher","unstructured":"Kwak N et al. MYcobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019;54(1):1801991. https:\/\/doi.org\/10.1183\/13993003.01991-2018.","DOI":"10.1183\/13993003.01991-2018"},{"issue":"8","key":"4696_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","volume":"23","author":"ML Wu","year":"2018","unstructured":"Wu ML, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502\u201319.","journal-title":"Drug Discov Today"},{"key":"4696_CR6","doi-asserted-by":"publisher","unstructured":"Mulyukin AL et al. Distinct Effects of Moxifloxacin and Bedaquiline on Growing and \u2018Non-Culturable\u2019 Mycobacterium abscessus. Microorganisms. 2023;11(11):2690. https:\/\/doi.org\/10.3390\/microorganisms11112690.","DOI":"10.3390\/microorganisms11112690"},{"key":"4696_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.micro.55.1.139","volume":"55","author":"LG Wayne","year":"2001","unstructured":"Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol. 2001;55:139\u201363.","journal-title":"Annu Rev Microbiol"},{"key":"4696_CR8","doi-asserted-by":"publisher","first-page":"1392606","DOI":"10.3389\/fmicb.2024.1392606","volume":"15","author":"HM Meliefste","year":"2024","unstructured":"Meliefste HM, et al. A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing. Front Microbiol. 2024;15:1392606.","journal-title":"Front Microbiol"},{"issue":"6","key":"4696_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1164\/rccm.201508-1586IM","volume":"193","author":"KP Fennelly","year":"2016","unstructured":"Fennelly KP, et al. Biofilm formation by Mycobacterium abscessus in a lung cavity. Am J Respir Crit Care Med. 2016;193(6):692\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4696_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1183\/13993003.01102-2015","volume":"46","author":"T Qvist","year":"2015","unstructured":"Qvist T, et al. Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection. Eur Respir J. 2015;46(6):1823\u20136.","journal-title":"Eur Respir J"},{"key":"4696_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1874285801711010053","volume":"11","author":"S Singh","year":"2017","unstructured":"Singh S, et al. Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. Open Microbiol J. 2017;11:53\u201362.","journal-title":"Open Microbiol J"},{"issue":"4","key":"4696_CR12","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s42770-021-00624-x","volume":"52","author":"MA Rather","year":"2021","unstructured":"Rather MA, Gupta K, Mandal M. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. Braz J Microbiol. 2021;52(4):1701\u201318.","journal-title":"Braz J Microbiol"},{"key":"4696_CR13","doi-asserted-by":"publisher","unstructured":"Lopeman RC et al. Mycobacterium abscessus: environmental bacterium turned clinical nightmare. Microorganisms. 2019;7(3):90. https:\/\/doi.org\/10.3390\/microorganisms7030090.","DOI":"10.3390\/microorganisms7030090"},{"key":"4696_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.aambs.2019.08.001","volume":"108","author":"BG Gordhan","year":"2019","unstructured":"Gordhan BG, Peters J, Kana BD. Application of model systems to study adaptive responses of Mycobacterium tuberculosis during infection and disease. Adv Appl Microbiol. 2019;108:115\u201361.","journal-title":"Adv Appl Microbiol"},{"key":"4696_CR15","doi-asserted-by":"publisher","first-page":"1137947","DOI":"10.3389\/fcimb.2023.1137947","volume":"13","author":"A Zhao","year":"2023","unstructured":"Zhao A, Sun J, Liu Y. Understanding bacterial biofilms: from definition to treatment strategies. Front Cell Infect Microbiol. 2023;13:1137947.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"4696_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41579-019-0158-9","volume":"17","author":"HC Flemming","year":"2019","unstructured":"Flemming HC, Wuertz S. Bacteria and archaea on Earth and their abundance in biofilms. Nat Rev Microbiol. 2019;17(4):247\u201360.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"4696_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/femsre\/fux010","volume":"41","author":"CW Hall","year":"2017","unstructured":"Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276\u2013301.","journal-title":"FEMS Microbiol Rev"},{"key":"4696_CR18","doi-asserted-by":"publisher","unstructured":"Perveen S, Pal S, Sharma R. Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target. RSC Med Chem. 2025;16(4):1476-1498. https:\/\/doi.org\/10.1039\/d4md00829d.","DOI":"10.1039\/d4md00829d"},{"key":"4696_CR19","doi-asserted-by":"publisher","first-page":"113139","DOI":"10.1016\/j.ejmech.2020.113139","volume":"212","author":"M Urban","year":"2021","unstructured":"Urban M, \u0160lachtov\u00e1 V, Brul\u00edkov\u00e1 L. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis. Eur J Med Chem. 2021;212:113139.","journal-title":"Eur J Med Chem"},{"key":"4696_CR20","doi-asserted-by":"publisher","unstructured":"Lee J et al. Differential in vitro activities of individual drugs and Bedaquiline-Rifabutin combinations against actively multiplying and Nutrient-Starved Mycobacterium abscessus. Antimicrob Agents Chemother. 2021;65(2):e02179-20. https:\/\/doi.org\/10.1128\/AAC.02179-20.","DOI":"10.1128\/AAC.02179-20"},{"issue":"1","key":"4696_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.17219\/pim\/149986","volume":"52","author":"JA Ghafil","year":"2022","unstructured":"Ghafil JA, \u0130brahim BMS, Zgair AK. Coating indwelling urinary catheters with Moxifloxacin prevents biofilm formation by burkholderia Cepacia. Polim Med. 2022;52(1):7\u201311.","journal-title":"Polim Med"},{"issue":"8","key":"4696_CR22","first-page":"483","volume":"115","author":"I Ozturk","year":"2014","unstructured":"Ozturk I, et al. In vitro effect of Moxifloxacin and rifampicin on biofilm formation by clinical MRSA isolates. Bratisl Lek Listy. 2014;115(8):483\u20136.","journal-title":"Bratisl Lek Listy"},{"issue":"Pt 1","key":"4696_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1099\/jmm.0.011981-0","volume":"59","author":"A Pompilio","year":"2010","unstructured":"Pompilio A, et al. Subinhibitory concentrations of Moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. J Med Microbiol. 2010;59(Pt 1):76\u201381.","journal-title":"J Med Microbiol"},{"issue":"11","key":"4696_CR24","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1128\/AAC.03482-14","volume":"58","author":"W Siala","year":"2014","unstructured":"Siala W, et al. Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2014;58(11):6385\u201397.","journal-title":"Antimicrob Agents Chemother"},{"key":"4696_CR25","doi-asserted-by":"publisher","first-page":"785573","DOI":"10.3389\/fmicb.2021.785573","volume":"12","author":"TK Nguyen","year":"2021","unstructured":"Nguyen TK, et al. Activity of Moxifloxacin against biofilms formed by clinical isolates of Staphylococcus aureus differing by their resistant or persister character to fluoroquinolones. Front Microbiol. 2021;12:785573.","journal-title":"Front Microbiol"},{"key":"4696_CR26","doi-asserted-by":"publisher","unstructured":"Daley CL et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. https:\/\/doi.org\/10.1183\/13993003.00535-2020.","DOI":"10.1183\/13993003.00535-2020"},{"issue":"8025","key":"4696_CR27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/d41586-024-02601-4","volume":"632","author":"A Dance","year":"2024","unstructured":"Dance A. Five ways science is tackling the antibiotic resistance crisis. Nature. 2024;632(8025):494\u20136.","journal-title":"Nature"},{"key":"4696_CR28","doi-asserted-by":"publisher","unstructured":"Rimal B et al. A BALB\/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration. Dis Model Mech. 2025;18(9):dmm052310. https:\/\/doi.org\/10.1242\/dmm.052310.","DOI":"10.1242\/dmm.052310"},{"issue":"8","key":"4696_CR29","doi-asserted-by":"publisher","first-page":"e0152023","DOI":"10.1128\/aac.01520-23","volume":"68","author":"Y Sun","year":"2024","unstructured":"Sun Y, et al. An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection. Antimicrob Agents Chemother. 2024;68(8):e0152023.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4696_CR30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/infdis\/jit614","volume":"209","author":"I Lerat","year":"2014","unstructured":"Lerat I, et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis. 2014;209(6):905\u201312.","journal-title":"J Infect Dis"},{"issue":"1","key":"4696_CR31","doi-asserted-by":"publisher","first-page":"e0247721","DOI":"10.1128\/spectrum.02477-21","volume":"10","author":"R Yao","year":"2022","unstructured":"Yao R, et al. Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis. Microbiol Spectr. 2022;10(1):e0247721.","journal-title":"Microbiol Spectr"},{"issue":"11","key":"4696_CR32","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1128\/AAC.00968-10","volume":"54","author":"J Poissy","year":"2010","unstructured":"Poissy J, et al. Should Moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother. 2010;54(11):4765\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4696_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/00498254.2019.1654633","volume":"50","author":"S Kobuchi","year":"2020","unstructured":"Kobuchi S, et al. Pharmacokinetics and lung distribution of macrolide antibiotics in sepsis model rats. Xenobiotica. 2020;50(5):552\u20138.","journal-title":"Xenobiotica"},{"issue":"7","key":"4696_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/bdd.767","volume":"32","author":"K Togami","year":"2011","unstructured":"Togami K, Chono S, Morimoto K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos. 2011;32(7):389\u201397.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"4696_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10787-012-0165-1","volume":"21","author":"PM Bartold","year":"2013","unstructured":"Bartold PM, et al. Antibacterial and Immunomodulatory properties of Azithromycin treatment implications for periodontitis. Inflammopharmacology. 2013;21(4):321\u201338.","journal-title":"Inflammopharmacology"},{"issue":"4","key":"4696_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jac\/dky526","volume":"74","author":"MM Ruth","year":"2019","unstructured":"Ruth MM, et al. A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74(4):935\u201343.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4696_CR37","doi-asserted-by":"publisher","first-page":"dlab004","DOI":"10.1093\/jacamr\/dlab004","volume":"3","author":"T Asami","year":"2021","unstructured":"Asami T, et al. Efficacy Estimation of a combination of triple antimicrobial agents against clinical isolates of Mycobacterium Abscessus subsp. Abscessus in vitro. JAC Antimicrob Resist. 2021;3(1):dlab004.","journal-title":"JAC Antimicrob Resist"},{"issue":"7","key":"4696_CR38","doi-asserted-by":"publisher","first-page":"e0024925","DOI":"10.1128\/aac.00249-25","volume":"69","author":"Y Jia","year":"2025","unstructured":"Jia Y, et al. An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity. Antimicrob Agents Chemother. 2025;69(7):e0024925.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4696_CR39","doi-asserted-by":"publisher","first-page":"e0053622","DOI":"10.1128\/aac.00536-22","volume":"66","author":"B Rimal","year":"2022","unstructured":"Rimal B, et al. T405, a new Penem, exhibits in vivo efficacy against M. abscessus and synergy with \u03b2-Lactams Imipenem and Cefditoren. Antimicrob Agents Chemother. 2022;66(6):e0053622.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 3","key":"4696_CR40","doi-asserted-by":"publisher","first-page":"151855","DOI":"10.1016\/j.scitotenv.2021.151855","volume":"807","author":"B Li","year":"2022","unstructured":"Li B, et al. Antibacterial peptide RP557 increases the antibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilm formation. Sci Total Environ. 2022;807(Pt 3):151855.","journal-title":"Sci Total Environ"},{"issue":"633","key":"4696_CR41","doi-asserted-by":"publisher","first-page":"eabj3860","DOI":"10.1126\/scitranslmed.abj3860","volume":"14","author":"JM Belardinelli","year":"2022","unstructured":"Belardinelli JM, et al. Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus. Sci Transl Med. 2022;14(633):eabj3860.","journal-title":"Sci Transl Med"},{"issue":"9","key":"4696_CR42","doi-asserted-by":"publisher","first-page":"e0242224","DOI":"10.1128\/spectrum.02422-24","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, et al. Efficacy of Carrimycin against Mycobacterium avium complex in vitro and in vivo. Microbiol Spectr. 2025;13(9):e0242224.","journal-title":"Microbiol Spectr"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04696-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04696-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04696-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:32:23Z","timestamp":1771417943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-025-04696-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4696"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04696-9","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiment involved in this paper had passed ethics of Beijing Chest Hospital affiliated Capital Medical University. There was no clinical trial number as our study did not involve people.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}